Histogen Announcement
Collapse
X
-
-
Are you sure? http://youtu.be/9SjQAfiKAk0?t=3m46s
why is it that IIa comes so fast but none of these companies have started IIb yet!(I'm not sure if BIM has).Comment
-
You're both wrong, yes Histogen is ahead of Replicel as it is about to commence a phase IIB study on humans, Replicel is commencing a phase IIA study on humans and their first study did grow hair on humans successfully. Replicel have stated that they may also be able to release the product in 2015 in a non-western jurisdiction if they have successful Phase IIA results.Comment
-
You're both wrong, yes Histogen is ahead of Replicel as it is about to commence a phase IIB study on humans, Replicel is commencing a phase IIA study on humans and their first study did grow hair on humans successfully. Replicel have stated that they may also be able to release the product in 2015 in a non-western jurisdiction if they have successful Phase IIA results.Comment
-
because according to: http://youtu.be/9SjQAfiKAk0?t=3m46s their phase IIa was successful (relatively) and they're moving to IIb?Comment
-
Hairloss is normally start and stop for a lot of people. I know mate with bald patches, who are not completely bald yet. I noticed the bald patch about 5 years ago on one.Comment
-
I mean source for: "Replicel is commencing a phase IIA study on humans and their first study did grow hair on humans successfully"
because according to: http://youtu.be/9SjQAfiKAk0?t=3m46s their phase IIa was successful (relatively) and they're moving to IIb?Comment
-
I mean source for: "Replicel is commencing a phase IIA study on humans and their first study did grow hair on humans successfully"
because according to: http://youtu.be/9SjQAfiKAk0?t=3m46s their phase IIa was successful (relatively) and they're moving to IIb?
What happened to Phase IIA?
Perhaps this explains it off their website:
Clinical Trial Protocol Extension (TS001-2013)
Based on advice received from the Paul-Ehrlich-Institut, the Company has initiated a follow-up extension to the TS001-2009 trial; named TS001-2013. This trial extension will continue the monitoring of the health of participants in TS001-2009 for a further 36 months thereby increasing the full safety data available from these participants to a full 5 years post-injection. This trial will completed in late 2016.
http://www.replicel.com/hair-regeneration/phase-i/Comment
-
Comment
Comment